Back to News
Market Impact: 0.2
MAIA Broadens Phase 3 Lung Cancer Study Footprint Across Europe
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
MAIA Biotechnology expanded its pivotal Phase 3 THIO-104 trial into Spain and Portugal after receiving regulatory clearance in both countries. The expansion advances patient enrollment and supports the company's planned interim survival analysis in 2027, representing a modest positive clinical-development milestone.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
MAIA0.55
More News
- Nvidia's CEO turmoil gives newly empowered Democrats fresh ammunition in pursuit of oversight
- Paraguay raids ex-president’s home: Why a bank crash brought down Pena
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- UniCredit CEO Plots Commerzbank Governance Overhaul
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- EU Plans Crackdown on Addictive Social Media and AI Bot Features